227 related articles for article (PubMed ID: 17210771)
21. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
Herbrecht R
Int J Clin Pract; 2004 Jun; 58(6):612-24. PubMed ID: 15311563
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
23. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
Vicenzi EB; Calore E; Decembrino N; Berger M; Perruccio K; Carraro F; Rossin S; Putti MC; Molinaro M; Tridello G; Cesaro S
Eur J Haematol; 2018 Mar; 100(3):315-322. PubMed ID: 29240266
[TBL] [Abstract][Full Text] [Related]
24. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.
Hoenigl M; Raggam RB; Salzer HJ; Valentin T; Valentin A; Zollner-Schwetz I; Strohmeier AT; Seeber K; Wölfler A; Sill H; Krause R
Int J Antimicrob Agents; 2012 Jun; 39(6):510-3. PubMed ID: 22481057
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
26. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.
Bernardo VA; Cross SJ; Crews KR; Flynn PM; Hoffman JM; Knapp KM; Pauley JL; Molinelli AR; Greene WL
Ann Pharmacother; 2013; 47(7-8):976-83. PubMed ID: 23737511
[TBL] [Abstract][Full Text] [Related]
27. Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy.
Chae H; Cho SY; Yu H; Cha K; Lee S; Kim M; Kim Y; Kim YJ; Kim HJ; Lee DG
Clin Chim Acta; 2015 Oct; 450():220-6. PubMed ID: 26319883
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
29. Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome.
Ceesay MM; Couchman L; Smith M; Wade J; Flanagan RJ; Pagliuca A
Med Mycol; 2016 Oct; 54(7):691-8. PubMed ID: 27161786
[TBL] [Abstract][Full Text] [Related]
30. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Cumpston A; Caddell R; Shillingburg A; Lu X; Wen S; Hamadani M; Craig M; Kanate AS
Antimicrob Agents Chemother; 2015 Aug; 59(8):4424-8. PubMed ID: 25987632
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy.
Park WB; Cho JY; Park SI; Kim EJ; Yoon S; Yoon SH; Lee JO; Koh Y; Song KH; Choe PG; Yu KS; Kim ES; Bang SM; Kim NJ; Kim I; Oh MD; Kim HB; Song SH
Int J Antimicrob Agents; 2016 Jul; 48(1):106-110. PubMed ID: 27234674
[TBL] [Abstract][Full Text] [Related]
32. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Krishna G; Ma L; Martinho M; O'Mara E
Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic and clinical evaluation of posaconazole.
Moore JN; Healy JR; Kraft WK
Expert Rev Clin Pharmacol; 2015 May; 8(3):321-34. PubMed ID: 25916666
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
[TBL] [Abstract][Full Text] [Related]
35. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.
Zhang H; Nguyen MH; Clancy CJ; Joshi R; Zhao W; Ensor C; Venkataramanan R; Shields RK
Antimicrob Agents Chemother; 2016 Jun; 60(6):3558-62. PubMed ID: 27021324
[TBL] [Abstract][Full Text] [Related]
37. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
Walravens J; Brouwers J; Spriet I; Tack J; Annaert P; Augustijns P
Clin Pharmacokinet; 2011 Nov; 50(11):725-34. PubMed ID: 21973269
[TBL] [Abstract][Full Text] [Related]
38. Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
Mauro M; Colombini A; Perruccio K; Zama D; D'Amico MR; Calore E; Carraro F; Muggeo P; Tridello G; Baretta V; Cesaro S
Mycoses; 2020 Jun; 63(6):604-609. PubMed ID: 32246512
[TBL] [Abstract][Full Text] [Related]
39. Relevance of timing for determination of posaconazole plasma concentrations.
Heinz WJ; Zirkel J; Kuhn A; Schirmer D; Lenker U; Keller D; Klinker H
Antimicrob Agents Chemother; 2011 Jul; 55(7):3621-3. PubMed ID: 21502619
[TBL] [Abstract][Full Text] [Related]
40. Posaconazole: a new broad-spectrum antifungal agent.
Kwon DS; Mylonakis E
Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
